I read with interest the article by Patauner and colleagues [1]. Even though most cases have a full recovery without significant sequelae, little is known about the mid- and long-term outcome of patients involved with the 2022 outbreak of monkeypox (MPX) [2,3]. Research has focused on zoonotic and human-to-human transmission and the clinical features of the eruption stage [2,3]. However, a spectrum of inflammatory disorders such as encephalomyelitis, myocarditis, and reactive polyarthritis (personal observation) can develop during the exanthem or after its disappearance [4,5].
